Edwards Lifesciences Corp 8-K

What Happened
Edwards Lifesciences Corporation (EW) reported that at its May 7, 2026 Annual Meeting stockholders approved an amendment and restatement of the company’s Long-Term Stock Incentive Compensation Program, increasing the share reserve by 7,000,000 to a new total of 341,500,000 shares. The company filed the full amended plan as Exhibit 10.1 to the Form 8-K. All director nominees were elected, the advisory vote on executive compensation ("say-on-pay") was approved, and PricewaterhouseCoopers LLP was ratified as the independent auditor for fiscal 2026.

Key Details

• Long-Term Stock Program: approved increase of 7,000,000 shares, raising the total limit to 341,500,000 shares; amended plan filed as Exhibit 10.1.
• Annual Meeting date: May 7, 2026.
• Director elections: all nominees elected (examples — Ramona Sequeira: 474,260,552 for; David T. Feinberg, MD: 473,746,144 for; Leslie C. Davis: 461,819,765 for).
• Other votes: say-on-pay approved (424,961,639 for vs. 50,924,101 against); PwC ratified as auditor (446,283,142 for vs. 56,814,075 against); approval of the amended long-term plan vote was 456,675,201 for vs. 19,210,539 against.

Why It Matters
Approval of the amended long-term stock incentive program gives Edwards more shares to grant as equity compensation, which management can use for executive and employee awards to retain and motivate talent. That can support growth plans but may also increase potential dilution for existing shareholders over time. Re-election of the board slate and approval of say-on-pay and the auditor indicate substantial shareholder support for current governance, compensation and audit arrangements.